Latest / Boardroom Conversations with Fexingo: CEOs, Strategy, and Corporate Leadership Explained
How the Novo Nordisk Board Built a Weight-Loss Empire
Episode 67 of Boardroom Conversations with Fexingo takes you inside the boardroom of Novo Nordisk, the Danish pharmaceutical giant that turned a diabetes drug into a weight-loss phenomenon. Lucas and Luna explore how the board navigated the explosive demand for Ozempic and Wegovy, managing supply constraints, pricing controversies, and a 400% stock surge over three years. They break down the board's decision to invest $6 billion in new manufacturing capacity, the ethical tightrope of marketing obesity drugs, and how they fended off competition from Eli Lilly. Specific numbers, dates, and…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.